BioAge Labs, Inc.（BIOA）资讯与事件BIOABioAge Labs, Inc.

BioAge Reports Q2 Revenue of $2.45M, Exceeds Expectations

Reports Q2 revenue $2.45M, consensus $1.5M. "NLRP3 sits at the apex of the inflammatory cascade that drives a range of diseases," said Kristen Fortney, CEO and co-founder of BioAge. "Our Phase 1 data show that BGE-102 is a potential best-in-class NLRP3 inhibitor: a well-tolerated once-daily pill that delivered up to 98% suppression of IL-1beta and brought hsCRP down to normal levels in most participants. We have dosed the first participant in QUELL-CV, our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk, with topline data anticipated in the second half of 2026. We also plan to start a second proof-of-concept trial this year in diabetic macular edema. These studies will test the broad potential of NLRP3 inhibition across inflammasome-driven diseases, and we are actively evaluating additional indications where this mechanism can deliver meaningful benefit. With a strong cash position, we are well positioned to advance BGE-102 across multiple opportunities and continue progressing the broader BioAge pipeline."

Apple Plummets Post-Earnings, Amazon Reports Strong Results

The major averages rallied on the final day of a turbulent month as traders weighed earnings from Apple and Amazon. While Amazon surged on its quarterly beat, Apple suffered a massive decline for their worst post-earnings drop in 13 years. The sharp losses came after the iPhone maker provided a lower-than-expected revenue outlook for Q4 in the face of foreign exchange issues and supply constraints.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q3 results butfor Q4 revenue growth amid foreign exchange issues and supply constraintsAmazonreported, with AWS net sales rising to $42.23BChevronreported better-than-expected Q2 earnings and revenue, with the company adding that it reportedExxon MobilreportedRedditreportedand provided upbeat Q3 revenue guidance2. WALL STREET CALLS:Benchmark and BTIGRobloxto Sell following quarterly resultsPiper Sandler and Cantor FitzgeraldReplimuneto Overweight following a postive FDA panel vote supporting RP1 approvalArgusBoston Scientificto HoldGuggenheimQuanta Servicesto BuyBMO CapitalNextpowerto Outperform3. AROUND THE WEB:T-Mobileexecutives have told the company's controlling shareholder, Deutsche Telekom, that they no longer support a proposed $300B merger between the two companies, Semafor reportsNXP Semiconductorsis in discussions to acquire Ambarella, FT reportsChimeis planning to cut about 10% of its workforce, or 150 employees, to capitalize on efficiencies created by AI, Bloomberg reportsTSMCis developing advanced AI chip packaging technology, internally called "EMIB-like," that is said to be similar to Intel'sEmbedded Multi-die Interconnect Bridge technique, The Information saysWSJ said some Teslaexecutives have been instructed by Elon Musk to prepare for a separation of the company's China business in the event of a potential merger with SpaceX, though Musk called the report "absurdly fake news."4. MOVERS:Integer Holdingsincreased afterthat KKRis near a deal to take the company privatenVent Electricwas higher in New York afterand listening additional manufacturing space in MinnesotaNewell Brandsand DexComgained in New York afterGoDaddyfell after, providing guidance for Q3, and narrowing its outlook for FY26BioAge Labsand Monte Rosa Therapeuticswere lower after Novo Nordisk'sZEUS triafor IL 6 inhibition5. EARNINGS/GUIDANCE:AbbVie, cut its EPS guidance for FY26, and provided guidance for Q3RBC Bearings, with EPS and revenue beating consensusColgate-Palmolive, with CEO Noel Wallace commenting on "strong broad-based top- and bottom-line results, despite a difficult operating environment"Eaton, provided guidance for Q3, and raised its outlook for FY26Magnaand raised its outlook for FY26INDEXES:The Dow rose 276.97, or 0.53%, to 52,485.03, the Nasdaq gained 251.68, or 1.00%, to 25,373.85, and the S&P 500 advanced 52.09, or 0.70%, to 7,489.72.

BioAge Labs Doses First Participant in QUELL-CV Trial

BioAge Labs announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. BGE-102 is being developed as a once-daily oral therapy, with cardiovascular risk reduction as the lead indication.